Answer
Intuniv (guanfacine) is indicated for ADHD in children and adolescents aged 6–17 years for whom stimulants are unsuitable, not tolerated or ineffective, and must be used within a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Sources for this answer
- Intuniv 4 mg prolonged-release tabletsTakeda UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 4Document updated
Sources checked